Prostat Kanserinde Hormonal Tedavi
Özet
Prostat kanserinde hormonal tedavi, androjenlerin tümör hücrelerinin devamlılığı üzerindeki etkisini engellemeyi amaçlayan ve ileri evre hastalıkta sıkça kullanılan etkili bir yöntemdir. Tedavinin temelini oluşturan cerrahi kastrasyon (bilateral orşiektomi), testosteron seviyelerini hızla kastre düzeylere düşürür. Medikal kastrasyon seçenekleri arasında yer alan GnRH agonistleri başlangıçta geçici bir testosteron artışına (alevlenme fenomeni) yol açarken, GnRH antagonistleri bu alevlenmeye neden olmadan doğrudan etki gösterir. Antiandrojenler ise androjen reseptörlerini bloke ederek çalışır; flutamid ve bikalutamid gibi birinci nesil ajanların yanı sıra, farmakolojik olarak daha güçlü olan enzalutamid ve apalutamid gibi ikinci nesil seçenekler de klinikte yer bulmaktadır. Ayrıca abirateron gibi ajanlarla androjen sentezi doğrudan inhibe edilebilmektedir. Bu tedaviler; sıcak basması, cinsel fonksiyon bozukluğu, kemik kırıkları, anemi ve metabolik sendrom gibi hastanın yaşam kalitesini ve genel durumunu etkileyen çeşitli yan etkilere yol açabilir. Klinik başarıyı artırmak adına, özellikle lokal ileri ve yüksek riskli hastalıklarda hormonal tedavinin radyoterapi veya dosetaksel kemoterapisi ile kombine edilmesi, sağkalım oranlarında anlamlı iyileşmeler sağlamaktadır. Tedavi seçiminde ajanların etki mekanizmaları ile yan etki profilleri titizlikle izlenmelidir.
Hormonal therapy in prostate cancer is an effective method widely used in advanced disease, aiming to prevent the effect of androgens on the survival of tumor cells. Surgical castration (bilateral orchiectomy), the cornerstone of treatment, rapidly reduces testosterone levels to castrate thresholds. Among medical castration options, GnRH agonists cause a temporary testosterone surge (flare phenomenon) at the beginning, whereas GnRH antagonists act directly without inducing this flare. Antiandrogens function by blocking androgen receptors; besides first-generation agents like flutamide and bicalutamide, pharmacologically more potent second-generation options such as enzalutamide and apalutamid are utilized. Additionally, androgen synthesis can be directly inhibited by agents like abiraterone. These therapies can lead to various side effects that impact the patient's quality of life and overall health, including hot flashes, sexual dysfunction, bone fractures, anemia, and metabolic syndrome. To enhance clinical success, combining hormonal therapy with radiotherapy or docetaxel chemotherapy, especially in locally advanced and high-risk diseases, provides significant improvements in survival rates. In treatment selection, the mechanism of action and side effect profiles of the agents must be meticulously monitored.
Referanslar
Huggins C. Studies on prostatic cancer. Archives of Surgery. 1941;43(2):209.
Huggins C, Scott W. Bilateral adrenalectomy in prostatic cancer. Annals of Surgery. 1945;122(6):1031-1041.
Mcleod D. Hormonal therapy: historical perspective to future directions. Urology. 2003;61(2):3-7.
Morley J. Testosterone Replacement and the Physiologic Aspects of Aging in Men. Mayo Clinic Proceedings. 2000;75(1):S83-S87.
Walsh P. Physiologic Basis for Hormonal Therapy in Carcinoma of the Prostate. Urologic Clinics of North America. 1975;2(1):125-140.
Bruchovsky N, Wilson J. The Conversion of Testosterone to 5α-Androstan-17β-ol-3-one by Rat Prostate in Vivo and in Vitro. Journal of Biological Chemistry. 1968;243(8):2012-2021.
Page S, Lin D, Mostaghel E, et al. Persistent Intraprostatic Androgen Concentrations after Medical Castration in Healthy Men. The Journal of Clinical Endocrinology & Metabolism. 2006;91(10):3850-3856.
Silver R, Wiley E, Davis D, et al. Expression and Regulation of Steroid 5α-Reductase 2 in Prostate Disease. Journal of Urology. 1994;152(2 Part 1):433-437.
Sun M, Choueiri T, Hamnvik O, et al. Comparison of Gonadotropin-Releasing Hormone Agonists and Orchiectomy. JAMA Oncology. 2016;2(4):500.
Heidenreich A, Aus G, Bolla M, et al. EAU Guidelines on Prostate Cancer. European Urology. 2008;53(1):68-80.
Molina A, Belldegrun A. Novel Therapeutic Strategies for Castration Resistant Prostate Cancer: Inhibition of Persistent Androgen Production and Androgen Receptor Mediated Signaling. Journal of Urology. 2011;185(3):787-794.
Schally A. Luteinizing hormone-releasing hormone analogs: their impact on the control of tumorigenesis. Peptides. 1999;20(10):1247-1262.
Limonta P, Marelli M, Moretti R. LHRH analogues as anticancer agents: pituitary and extrapituitary sites of action. Expert Opinion on Investigational Drugs. 2001;10(4):709-720.
Schellhammer P, Sharifi R, Block N, et al. Nical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: Final report of a double-blind, randomized, multicenter trial. Urology. 1997;50(3):330-336.
Tsushima T, Nasu Y, Saika T, et al. Optimal Starting Time for Flutamide to Prevent Disease Flare in Prostate Cancer Patients Treated with a Gonadotropin-Releasing Hormone Agonist. Urologia Internationalis. 2001;66(3):135-139.
Weckermann D, Harzmann R. Hormone Therapy in Prostate Cancer: LHRH Antagonists versus LHRH Analogues. European Urology. 2004;46(3):279-284.
Gonzalez-Barcena D, Vadillo-Buenfil M, Cortez-Morales A, et al. Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord. Urology. 1995;45(2):275-281.
Crawford E, Schellhammer P, McLeod D, et al. Androgen Receptor Targeted Treatments of Prostate Cancer: 35 Years of Progress with Antiandrogens. Journal of Urology. 2018;200(5):956-966.
Parys B, Hamid S, Thomson R. Severe Hepatocellular Dysfunction following Cyproterone Acetate Therapy. British Journal of Urology. 1991;67(3):312-313.
Iversen P. Antiandrogen monotherapy: indications and results. Urology. 2002;60(3):64-71.
McLeod D. Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer. The Oncologist. 1997;2(1):18-27.
Han M, Nelson J. Non-steroidal anti-androgens in prostate cancer - current treatment practice. Expert Opinion on Pharmacotherapy. 2000;1(3):443-449.
Thole Z, Manso G, Salgueiro E, et al. Hepatotoxicity Induced by Antiandrogens: A Review of the Literature. Urologia Internationalis. 2004;73(4):289-295.
Scher H, Fizazi K, Saad F, et al. Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy. New England Journal of Medicine. 2012;367(13):1187-1197.
Smith M, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. New England Journal of Medicine. 2018;378(15):1408-1418.
Ponder B, Shearer R, Pocock R, et al. Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. British Journal of Cancer. 1984;50(6):757-763.
Trachtenberg J, Halpern N, Pont A. Ketoconazole: A Novel and Rapid Treatment for Advanced Prostatic Cancer. Journal of Urology. 1983;130(1):152-153.
Chang A, Yeap B, Davis T, et al. Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol. Journal of Clinical Oncology. 1996;14(8):2250-2257.
Attard G, Reid A, Yap T, et al. Phase I Clinical Trial of a Selective Inhibitor of CYP17, Abiraterone Acetate, Confirms That Castration-Resistant Prostate Cancer Commonly Remains Hormone Driven. Journal of Clinical Oncology. 2008;26(28):4563-4571.
Boccardo F, Pace M, Rubagotti A, et al. Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. European Journal of Cancer. 1993;29(8):1088-1093.
CASPER R, YEN S. NEUROENDOCRINOLOGY OF MENOPAUSAL FLUSHES: AN HYPOTHESIS OF FLUSH MECHANISM. Clinical endocrinology. 1985;22(3):293-312.
Nishiyama T, Kanazawa S, Watanabe R, Terunuma M, Takahashı K. Influence of hot flashes on quality of life in patients with prostate cancer treated with androgen deprivation therapy. International Journal of Urology. 2004;11(9):735-741.
Smith M, Eastham J, Gleason D, et al N. Randomized Controlled Trial of Zoledronic Acid to Prevent Bone Loss in Men Receiving Androgen Deprivation Therapy for Nonmetastatic Prostate Cancer. Journal of Urology. 2003;169(6):2008-2012.
Hanks G, Pajak T, Porter A, et al. Phase III Trial of Long-Term Adjuvant Androgen Deprivation After Neoadjuvant Hormonal Cytoreduction and Radiotherapy in Locally Advanced Carcinoma of the Prostate: The Radiation Therapy Oncology Group Protocol 92–02. Journal of Clinical Oncology. 2003;21(21):3972-3978.
Smith M, Egerdie B, Toriz N, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine. 2009;361(8):745-755.
Smith M. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63(4):742-745.
Smith M, Lee H, Nathan D. Insulin Sensitivity during Combined Androgen Blockade for Prostate Cancer. The Journal of Clinical Endocrinology & Metabolism. 2006;91(4):1305-1308.
Braga-Basaria M, Dobs A, Muller D, et al. Metabolic Syndrome in Men With Prostate Cancer Undergoing Long-Term Androgen-Deprivation Therapy. Journal of Clinical Oncology. 2006;24(24):3979-3983.
Autorino R, Perdonà S, D'Armiento M, et al. Gynecomastia in patients with prostate cancer: update on treatment options. Prostate Cancer and Prostatic Diseases. 2006;9(2):109-114.
Lee F, Siders DB, McHug TA, et al. Long-term follow-up of stages T2-T3 prostate cancer pretreated with androgen ablation therapy prior to radical prostatectomy. Anticancer Research. 1997 May-Jun;17(3A):1507-1510.
Klotz L, Goldenberg S, Jewett M, et al. Long-term Followup of a Randomized Trial of 0 Versus 3 Months of Neoadjuvant Androgen Ablation Before Radical Prostatectomy. Journal of Urology. 2003;170(3):791-794.
Soloway M, Pareek K, Sharifi R, et al. Neoadjuvant androgen ablation before radical prostatectomy in ct2bnxmo prostate cancer: 5-year results. Journal of Urology. 2002;167(1):112-116.
Witjes W, Schulman C, Debruyne F. Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2–3 N0 M0 prostatic carcinoma. Urology. 1997;49(3):65-69.
Granfors T, Modig H, Damber J, et al. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: a prospective randomized study. Journal of Urology. 1998;159(6):2030-2034.
Bolla M, Gonzalez D, Warde P, et al. Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin. New England Journal of Medicine. 1997;337(5):295-300.
Tannock I, Wit R, Berry W, et al. Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer. New England Journal of Medicine. 2004;351(15):1502-1512.
Gravis G, Fizazi K, Joly F, et al. Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2013;14(2):149-158.
Sweeney C, Chen Y, Carducci M, et al. Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine. 2015;373(8):737-746.
James N, Sydes M, Clarke N, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. The Lancet. 2016;387(10024):1163-1177.
